

Market insights summary

# Asia Pacific aesthetic injectable market

## What's trending and new

The Asia Pacific aesthetic injectable market will continue to see new offerings and indications launched by multinational players and domestic competitors

- The Asia Pacific aesthetic injectable market will continue to expand with the continued emergence of new products and indications offered by leading global and regional players. The presence of domestic manufacturers offering cost-effective alternatives will increase the affordability of aesthetic injectable treatments, supporting access to and adoption of the procedures in the Asia Pacific countries.

Hybrid fillers, including brands from domestic competitors, offer significant revenue potential in the Asia Pacific region

- Hybrid fillers provide an immediate lift through their HA component, while their non-HA component contributes to long-term collagen biostimulation and delivers natural-looking results. The products are gaining traction globally and offer significant revenue potential in the Asia Pacific region as well.
- South Korean competitors like PharmaResearch and VAIM are actively expanding across Asia Pacific countries. PharmaResearch's Rejuran is approved in key markets such as Thailand, Japan, and China, while Vaim has merged with Vaim Global to streamline operations and promote its Juvelook fillers regionally. These moves highlight the growing influence of domestic competitors in the hybrid filler segment.

Access more insights and data in the [report](#).  
[Speak to our team](#) to see how we can power your innovation.

## 2024 Asia Pacific aesthetic injectable market snapshot


**\$1.9B**

Market revenue


**6.6%**

CAGR ('19-'34)


Asia Pacific aesthetic injectable market by country



Asia Pacific BTX vs dermal filler markets, 2024



Procedure growth by product type



BTX = Botulinum toxin  
 HA = Hyaluronic acid

2024 Asia Pacific aesthetic injectable competitive landscape

